CSACI position statement: epinephrine auto-injectors and children < 15 kg

Allergy, Asthma & Clinical Immunology

Michelle Halbrich¹  Douglas P. Mack⁵  Stuart Carr²  Wade Watson⁴  Harold Kim³ 

[1] Paediatric Allergy, Asthma and Clinical Immunology, Winnipeg Clinic, University of Manitoba, Winnipeg, MB, Canada

[2] Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

[3] McMaster University, Hamilton, ON, Canada

[4] Department of Pediatrics, Dalhousie University, Head, Division of Allergy, IWK Health Centre, Halifax, NS, Canada

[5] Department of Pediatrics, McMaster University, Pediatric Allergy, Asthma and Immunology, Assistant Clinical Professor, McMaster University, Joseph Brant Memorial Hospital, Burlington, ON, Canada

关键词: Allergy;    CSACI position statement;    Infant;    Anaphylaxis;    Epinephrine;   

Others  :  1218605
DOI  :  10.1186/s13223-015-0086-9

 received in 2015-05-27, accepted in 2015-06-02,  发布年份 2015

【 摘 要 】

Epinephrine (adrenaline) is the treatment of choice for anaphylaxis. While other medications, including H ₁ -antihistamines, H ₂ -antihistamines, corticosteroids, and inhaled beta-2 agonists are often used to treat anaphylaxis in the emergency setting, none of these medications has been shown to reverse anaphylaxis. Fatal anaphylaxis is related to the delayed use of epinephrine. In community settings, epinephrine is available as an auto-injector in two doses, 0.15 mg and 0.3 mg. The recommended dose for children is 0.01 mg per kilogram. For infants at risk of anaphylaxis in the community, there are few options with regard to providing an optimal epinephrine dose for first-aid treatment. The Canadian Society of Allergy and Immunology (CSACI) therefore recommends, for the child weighing less than 15 kg, given the lack of a suitable alternative, prescribing the 0.15 mg epinephrine autoinjector. Adverse effects of an epinephrine dose of 0.15 mg given intramuscularly in infants or children weighing less than 15 kg are expected to be mild and transient at the plasma epinephrine concentrations achieved; therefore, these effects need to be measured against the consequences of not receiving epinephrine at all, which can include fatality.

【 授权许可】

   
2015 Halbrich et al.

【 参考文献 】

• [1]Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J et al.. World allergy organization. World allergy organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011; 127(3):587-93.
• [2]Cheng A. Emergency treatment of anaphylaxis in infants and children. Paediatr Child Health. 2011; 16(1):35-40.
• [3]Kim H, Fischer D. Anaphylaxis. Allergy Asthma Clin Immunol. 2011; 7 Suppl 1:S6. BioMed Central Full Text
• [4]Sheikh A, Shehata YA, Brown SGA, Simons FER. Adrenaline for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2009; 64:204-12.
• [5]EpiPen® package inserts. http://pfizer. ca/sites/g/files/g10017036/f/201410/EpiPen_PM_E_153460_13Mar2012.pdf webcite
• [6]Allerject® package inserts. http://products. sanofi.ca/en/allerject.pdf webcite
• [7]Simons FER. First-aid treatment of anaphylaxis to food: Focus on epinephrine. J Allergy Clin Immunol. 2004; 113:837-44.
• [8]Stecher D, Bulloch B, Sales J, Schaefer C, Keahey L. Epinephrine auto-injectors: is needle length adequate for delivery of epinephrine intramuscularly? Pediatrics. 2009; 124(1):65-70.
• [9]Kim L, Nevis I, Tsai G, Dominic A, Potts R, Chiu J et al.. Children <15 kg with food allergy may be at risk of having epinephrine auto-injectors administered into bone Allergy Asthma. Clin Immunol. 2014; 10(1):40.
• [10]Macdougall CF, Cant AJ, Colver AF. How dangerous is food allergy in childhood? The incidence of severe and fatal allergic reactions across the UK and Ireland. Arch Dis Child. 2002; 86(4):236-9.
• [11]Simons FE, Chan ES, Gu X, Simons KJ. Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical? J Allergy Clin Immunol. 2001; 108(6):1040-4.
• [12]Sicherer SH, Simons FE. Section on allergy and immunology, American academy of pediatrics. Self-injectable epinephrine for first-aid management of anaphylaxis. Pediatrics. 2007; 119(3):638-46.
• [13]Sicherer SH. Self-injectable epinephrine: no size fits all! Ann Allergy Asthma Immunol. 2001; 86(6):597-8.
• [14]Simons FE, Gu X, Silver NA, Simons KJ. EpiPen Jr versus EpiPen in young children weighing 15–30 kg at risk for anaphylaxis. J Allergy Clin Immunol. 2002; 109(1):171-5.
• [15]Tupper J, Visser S. Anaphylaxis: a review and update. Can Fam Physician. 2010; 56(10):1009-11.
• [16]Kanwar M, Irvin CB, Frank JJ, Weber K, Rosman H. Confusion about epinephrine dosing leading to iatrogenic overdose: a life-threatening problem with a potential solution. Ann Emerg Med. 2010; 55(4):341-4.
• [17]Tarim O, Anderson VM, Lifshitz F. Fatal anaphylaxis in a very young infant possibly due to a partially hydrolyzed whey formula. Arch Pediatr Adolesc Med. 1994; 148(11):1224-9.
• [18]Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009; 123(2):434-42.
• [19]Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992; 327(6):380-4.
• [20]Gold MS, Sainsbury R. First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen). J Allergy Clin Immunol. 2000; 106(1 Pt 1):171-6.
• [21]Simons FER. Anaphylaxis in infants: Can recognition and management be improved? J Allergy Clin Immunol. 2007; 120:537-40.